# Clofarabine Pre-conditioning With Allogeneic Transplant for Acute Myeloid Leukaemia (AML)

> **NCT01422603** · PHASE1,PHASE2 · COMPLETED · sponsor: **University Hospital Southampton NHS Foundation Trust** · enrollment: 9 (actual)

## Conditions studied

- Acute Myeloid Leukaemia
- Myelodysplasia

## Interventions

- **DRUG:** Clofarabine
- **DRUG:** Clofarabine

## Key facts

- **NCT ID:** NCT01422603
- **Lead sponsor:** University Hospital Southampton NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02
- **Primary completion:** 2014-05
- **Final completion:** 2015-03-31
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2018-09-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01422603

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01422603, "Clofarabine Pre-conditioning With Allogeneic Transplant for Acute Myeloid Leukaemia (AML)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01422603. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*